Gypto Pharma signs a strategic agreement with Bacha Group as Egypt seeks to strengthen pharmaceutical exports and regional healthcare supply chains across Africa.
Egypt has taken another step in its strategy to expand pharmaceutical exports across Africa after Gypto Pharma City signed a memorandum of understanding (MoU) with Djibouti-based Bacha Group to strengthen regional pharmaceutical distribution and improve access to Egyptian-made medicines across the Horn of Africa and wider East African markets. The partnership supports Cairo’s broader objective of positioning Egypt as a regional manufacturing and export hub for high-value pharmaceutical products.
The agreement was signed during the visit of a high-level Djiboutian delegation led by Hibo Bacha, Chairperson of Bacha Group, Vice Chairperson of the Egyptian-Djiboutian Business Council and President of the Djiboutian Businesswomen Association. Discussions focused on accelerating the registration and distribution of Egyptian medicines in Djibouti and neighbouring markets while strengthening bilateral cooperation in pharmaceutical manufacturing, healthcare resilience and industrial development.
During the visit, the delegation toured Gypto Pharma’s manufacturing facilities and production lines operating in accordance with international Good Manufacturing Practice (GMP) standards. The two sides also explored the gradual localisation of selected pharmaceutical operations by utilising Bacha Group’s logistics and industrial infrastructure in Djibouti, although no investment value or implementation timetable has been announced.
The partnership highlights Djibouti’s strategic role as a logistics gateway linking Red Sea shipping routes with the Horn of Africa and inland East African markets. By combining Egypt’s pharmaceutical manufacturing base with Djibouti’s regional distribution capabilities, the agreement aims to improve market access, strengthen pharmaceutical supply chains and support more efficient delivery of medicines across rapidly growing healthcare markets.
The initiative also aligns with Egypt’s broader industrial strategy of increasing higher-value manufactured exports under the African Continental Free Trade Area (AfCFTA), which seeks to deepen regional trade and industrial integration. As one of Egypt’s fastest-growing manufacturing industries, the pharmaceutical sector has become a key pillar of the country’s export diversification strategy, with policymakers increasingly targeting African markets to drive long-term industrial growth and healthcare cooperation.
Related news:
Gulf Investors Eye Stake in Egypt’s $150m Arab API Pharmaceutical Ingredients Project
Pharco Pharmaceuticals Plans EGP 1.5bn Investment to Expand Production and Exports
Read also:
Egypt Launches Saqqara Infrastructure Upgrade to Expand Cultural Tourism
Egypt Attracts More Than $1.1bn in New Hospitality Investment for Sharm El Sheikh
